Prof. Mohssen Elalfy

Ain Shams University, Egypt

Email: elalfy@hotmail.com

Qualifications

1986 Ph.D., Ain Shams University

1982 M.Sc., Ain Shams University

1978 B.Sc., Ain Shams University

Publications (selected)

1. Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program. El Danasoury AS, Eissa DG, Abdo RM, Elalfy MS. Transfusion. 2011 Jul 11. DOI: 10.1111/j.1537-2995.2011.03234.x. [Epub ahead of print] PMID: 21745214.
2. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study. Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, Roubert B, El-Beshlawy A. Eur J Haematol. 2011 Jun 11. DOI: 10.1111/j.1600-0609.2011.01661.x. [Epub ahead of print] PMID: 21668501 [PubMed - as supplied by publisher].
3. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Ann Hematol. 2011 Feb 12. [Epub ahead of print] PMID: 21318572 [PubMed - as supplied by publisher].
4. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. Elalfy MS, Abdin IA, El Safy UR, Ibrahim AS, Ebeid FS, Salem DS. Hematol Oncol Stem Cell Ther. 2010; 3(4): 174-8. PMID: 21150236.
5. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Haematologica. 2011 Jan; 96(1): 48-54. Epub 2010 Nov 11. PMID: 21071497.
6. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial. Elalfy MS, Elbarbary NS, Abaza HW. Eur J Pediatr. 2011 Apr; 170(4): 461-7. Epub 2010 Oct 6. PMID: 20924607.
7. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB; EPIC study investigators. Blood. 2010 Oct 7; 116(14): 2448-54. Epub 2010 Jun 21. PMID: 20566896.
8. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators. Leuk Res. 2010 Sep; 34(9): 1143-50. Epub 2010 May 6. PMID: 20451251.
9. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, Baladi JF, Habr D, Kriemler-Krahn U, El-Beshlawy A. Acta Haematol. 2010; 123(4): 220-5. Epub 2010 Apr 27. PMID: 20424435.
10. Predictors of chronic idiopathic thrombocytopenic purpura. ElAlfy M, Farid S, Abdel Maksoud A. Pediatr Blood Cancer. 2010 Jul 1; 54(7): 959-62. PMID: 20405514.
11. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Blood. 2010 Mar 25; 115(12): 2364-71. Epub 2009 Dec 8. PMID: 19996412.
12. Intracranial hemorrhage in acute and chronic childhood immune thrombocytopenic purpura over a ten-year period: an Egyptian multicenter study. Elalfy M, Elbarbary N, Khaddah N, Abdelwahab M, El Rashidy F, Hassab H, Al-Tonbary Y. Acta Haematol. 2010; 123(1): 59-63. Epub 2009 Dec 2. PMID: 19955713.
13. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Haematologica. 2010 Apr; 95(4): 557-66. Epub 2009 Nov 30. PMID: 19951979.
14. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A. Eur J Haematol. 2009 Jun; 82(6): 458-65. Epub 2009 Jan 28. PMID: 19187278.
15. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Imbach P, Kühne T, Müller D, Berchtold W, Zimmerman S, Elalfy M, Buchanan GR. Pediatr Blood Cancer. 2006 Mar; 46(3): 351-6. PMID: 16086422.
16. Overwhelming postsplenectomy infection: is quality of patient knowledge enough for prevention? El-Alfy MS, El-Sayed MH. Hematol J. 2004; 5(1): 77-80. PMID: 14745434.
17. Management of CML in the Pediatric Age Group: Imatinib Mesylate or SCT. El-Alfy MS, Al-Haddad AM, Hamed AA. J Egypt Natl Canc Inst. 2010 Dec; 22(4): 227-32. PMID: 21863074.
18. Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A. Abdel-Messih IY, Habashy DM, Moftah SG, El-Alfy M. Haemophilia. 2011 May; 17(3): 490-3. DOI: 10.1111/j.1365-2516.2010.02447.x. Epub 2011 Mar 4. PMID: 21371185.